UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of: November 2026
Commission
file number: 001-36578
ENLIVEX
LTD.
(Translation
of registrant’s name into English)
14
Einstein Street, Nes Ziona, Israel 7403618
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
On
November 18, 2026, Enlivex Ltd., a company organized
under the laws of the State of Israel (the “Company”), issued a press release
announcing that the independent Data and Safety Monitoring Board overseeing the Company's randomized, double-blind, placebo-controlled
Phase IIb trial evaluating Allocetra™ in patients with primary age-related knee osteoarthritis has completed an interim safety
review of data from 85 patients randomized and dosed in the trial. A copy of the press release is furnished herewith as Exhibit 99.1
and is incorporated herein by reference.
| Exhibit
No. |
|
| |
|
| 99.1 |
Press Release |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Enlivex
Ltd. |
| |
(Registrant) |
| |
|
| |
By: |
/s/
Oren Hershkovitz |
| |
Name:
Title: |
Oren Hershkovitz
Chief Executive Officer |
Date:
November 18, 2026
Exhibit
99.1
Enlivex
Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial
Nes-Ziona, Israel, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (“Enlivex” or the “Company”), a quality
longevity company powered by a prediction markets treasury, today announced that the independent Data and Safety Monitoring Board (DSMB)
overseeing the Company’s randomized, double-blind, placebo-controlled Phase IIb trial evaluating Allocetra™ in patients with
primary age-related knee osteoarthritis has completed an interim safety review of data from 85 patients randomized and dosed in the trial.
Following review of the data, the DSMB confirmed that the safety profile of Allocetra™ allows the Company to continue enrolling
patients in the trial as planned.
“The
outcome of this interim review, covering 85 patients randomized and dosed in the trial, appears consistent with the favorable safety
profile observed in our Phase I/IIa trial,” said Einat Galamidi, Chief Medical Officer of Enlivex. “We are pleased with the
DSMB’s decision that the trial will continue as planned and designed, and we remain focused on executing the Phase IIb trial and
look forward to reporting topline data.”
About
the Phase IIb Trial
The
Phase IIb trial (NCT07580716), is a randomized, double-blind, placebo-controlled, global, multicenter, clinical trial which is designed
to evaluate the efficacy and safety of 3 intra-articular injections of Allocetra™ in patients 64 and older with moderate-to-severe
symptomatic primary knee osteoarthritis. The trial is planned to enroll approximately 182 patients from clinical centers in the United
States, Denmark and Poland. Key efficacy endpoints include changes from baseline of pain and physical function compared with placebo,
measured at three- and six-month periods following treatment. Additional endpoints include changes in quality-of-life measures, functional
mobility assessments and one year follow-up.
About
Knee Osteoarthritis
Osteoarthritis
(OA) is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to continue
to grow substantially, with knee OA (KOA) being the most prevalent form. There are currently no approved disease-modifying therapies;
treatment is largely limited to pain relief, intra-articular steroids, or surgery, and the burden increases sharply with age. By age
60, KOA affects roughly 30% of the population, and about half of KOA patients are 60 years of age or older. This demographic is expanding
with global aging trends, underscoring the need for new, durable therapies.
About
Enlivex
Enlivex
is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage
immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition
to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain Protocol, the leading decentralized
prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure
to the emerging prediction markets ecosystem.
Forward-looking
statements
This
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,”
“plans,” “projects,” “will,” “may,” “anticipates,” “believes,”
“should,” “would,” “could,” “intends,” “estimates,” “suggests,”
“target,” “has the potential to,” “goal,” and other words of similar meaning, including statements
relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the
expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased
token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s
ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value
creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological
and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results
of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.
Each
forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk that
results from subgroup analyses and small patient populations, including those described in this press release, may not be replicated
in larger trials, including the Company’s ongoing Phase IIb trial; the risk that topline data may change following a more comprehensive
review of the data; the risk that RMAT designation may not lead to a faster development or regulatory review process and does not increase
the likelihood of approval; risks related to the timing, conduct and outcome of clinical trials and regulatory submissions; the risk
of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial,
political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature
of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings,
trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated
with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company
operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally;
risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the
Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only
as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required
by applicable law.
Enlivex
contact
Shachar
Shlosberger
CFO
Enlivex
Ltd.
shachar@enlivex.com